Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Breast 2Thoracic 1Dermatologic 1

Conditions

Breast Neoplasms 14Brain Neoplasms 6Ovarian Neoplasms 4Melanoma 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Sarcoma 2Prostatic Neoplasms 2Neoplasms, Second Primary 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Astrocytoma 1

Interventions

Temozolomide 2sacubitril and valsartan sodium hydrate drug combination 1Interviews as Topic 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Second Primary × Temozolomide × Breast × Clear all
NCT00638963 2017-06-14

STOP

Merck Sharp & Dohme LLC

Phase 2 Terminated
6 enrolled 9 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasms, Second Primary

NCT00629187 2012-04-27

CN-306

Tufts Medical Center

Phase 1 Terminated
2 enrolled
BreastCNSDermatologicThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Central Nervous System Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡